A 16-year-old Japanese boy presented to our hospital with a subcutaneous nodule on the right palm that had developed over 4 months. He reported a history of “ganglion cyst” in the same area that had been treated with drainage at another clinic 3 years earlier.

Clinical examination revealed a tender, mobile subcutaneous nodule 12×12 mm on the right palm near the antithenar eminence. Slight, poorly demarcated pigmentation was observed on the surface of the nodule (Fig. 1). Ultrasonography confirmed that there was no blood flow inside the tumour. Surgical excision was performed under the clinical diagnosis of recurrent ganglion cyst. The excised specimen revealed the proliferation of atypical cells with vesicular nuclei and mild myxoid areas (Fig. 2A), mixed with prominent inflammatory cell infiltrates of lymphocytes and plasma cells (Fig. 2B). Large cells with atypia were also noted, part of which resembled Reed–Sternberg cells (Fig. 2C). Immunohistochemically, these atypical cells were positive for CD68 (KP-1, PGM-1) and negative for alpha-smooth muscle actin, CD34 and AE1/AE3.

What is your diagnosis? See next page for answer.
**ANSWERS TO QUIZ**

**Subcutaneous Nodule on the Right Palm of a Young Boy: A Commentary**

Acta Derm Venereol 2017; 97: 1150–1151.

**Diagnosis: Myxoinflammatory fibroblastic sarcoma**

Myxoinflammatory fibroblastic sarcoma (MIFS) is a rare, low-grade, soft-tissue sarcoma that was first described by several different groups in 1998 (1–3). Fewer than 200 cases have been reported (4). MIFS is clinically characterized by its appearance on distal extremities. Tejwani et al. (5) reported that there is no predilection for sex or age, with ages ranging from 4 to 87 years. Histologically, MIFS is composed of hypocellular areas and dense cellular areas. The former areas are myxoid and fibrous. The latter areas comprise prominent inflammatory cell infiltrates, such as eosinophils, neutrophils, lymphocytes and plasma cells, as well as large atypical tumour cells, including Reed-Sternberg-like cells and lipoblast-like cells (1, 4, 6). These histological characteristics were consistent with the present case.

Immunohistochemically, no specific findings have been reported. The tumour cells are positive for vimentin, focally positive for CD34 and CD68, and negative for S-100 protein, alpha-smooth muscle actin, muscle-specific actin, AE1/AE3, CAM 5.2, desmin, CD15, CD45, HMB45, Epstein-Barr virus latent-membrane protein, EMA and GFAP (1–4, 7).

Because of its clinical presentation and histological characteristics, even experienced dermatologists and pathologists can misdiagnose MIFS as ganglion cyst, tenosynovitis and non-neoplastic disease (5). The present case was initially diagnosed as “ruptured ganglion cyst.”

MIFS has been reported to have a relatively low potential for metastasis, but a high risk of recurrence. The metastasis and recurrence rates have been reported as 3.1% and 31.3%, respectively (5). Lombardi et al. (8) reported that cancer-related death was seen in only one case of 138 patients with MIFS. No standard treatment protocol exists. Ieremia et al. (4) recommend wide local excision with 5-year follow-up observation for MIFS. Some reports have indicated that surgical excision with radiation therapy maintained a good clinical course (5, 9).

Although MIFS is rare, it is important for clinical dermatologists to keep it in mind when repeated recurrences of “ganglion cyst” are observed, especially on the distal extremities. Excision and skin biopsies will help diagnose MIFS correctly with characteristic histopathological findings.

The authors declare no conflicts of interest.

**REFERENCES**

1. Montgomery EA, Devaney KO, Giordano TJ, Weiss SW. Inflammatory myxohyaline tumor of distal extremities with virocyte or Reed-Sternberg-like cells: a distinctive lesion with features simulating inflammatory conditions, Hodgkin’s disease, and various sarcomas. Mod Pathol 1998; 11: 384–391.
2. Michal M. Inflammatory myxoid tumor of the soft parts with bizarre giant cells. Pathol Res Pract 1998; 194: 529–533.
3. Meis-Kindblom JM, Kindblom LG. Acral myxoinflammatory fibroblastic sarcoma: a low-grade of tumor of the hands and feet. Am J Surg Pathol 1998; 22: 911–924.
4. Ieremia E, Thway K. Myxoinflammatory fibroblastic sarcoma; morphologic and genetic updates. Arch Pathol Lab Med 2014; 138: 1406–1411.
5. Tejwani A, Kobayashi W, Chen YL, Rosenberg AE, Yoon S, Raskin KA, et al. Management of acral myxoinflammatory fibroblastic sarcoma. Cancer 2010; 116: 5733–5739.
6. Baumhoer D, Glatz K, Schulten HJ, Füzesi L, Fricker R, Kettelhack C, et al. Myxoinflammatory fibroblastic sarcoma: investigations by comparative genomic hybridization of two cases and review of the literature. Virchows Arch 2007; 451: 923–928.
7. Chahdi H, Damiri A, Oukabli M, Albouzidi A, Bouabid S, Lazrek K. Acral myxoinflammatory fibroblastic sarcoma. Orthop Traumatol Surg Res 2010; 96: 597–599.
8. Lombardi R, Jovine E, Zanini N, Salone MC, Gambarotti M, Righi A, et al. A case of lung metastasis in myxoinflammatory fibroblastic sarcoma: analytical review of one hundred and thirty eight cases. Int Orthop 2013; 37: 2429–2436.
9. Silver AG, Baynosa RC, Mahabir RC, Wang WZ, Zamboni WA, Khiabani KT. Acral myxoinflammatory fibroblastic sarcoma: a case report and literature review. Can J Plast Surg 2013; 21: 92–94.